Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 May 3;145(18):1387-1397.
doi: 10.1161/CIRCULATIONAHA.121.057008. Epub 2022 Apr 25.

Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial

Axel C P Diederichsen  1 , Jes S Lindholt  2 , Sören Möller  3 , Kristian A Øvrehus  1 , Søren Auscher  4 , Jess Lambrechtsen  4 , Susanne E Hosbond  5 , Dilek H Alan  5 , Grazina Urbonaviciene  6 , Søren W Becker  6 , Maise H Fredgart  1 , Selma Hasific  1 , Lars Folkestad  7 , Oke Gerke  8 , Lars Melholt Rasmussen  9 , Jacob E Møller  10 , Hans Mickley  1 , Jordi S Dahl  1
Affiliations
Randomized Controlled Trial

Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial

Axel C P Diederichsen et al. Circulation. .

Abstract

Background: Menaquinone-7 (MK-7), also known as vitamin K2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC) in patients with aortic stenosis.

Methods: In a randomized, double-blind, multicenter trial, men from the community with an AVC score >300 arbitrary units (AU) on cardiac noncontrast computer tomography were randomized to daily treatment with tablet 720 µg MK-7 plus 25 µg vitamin D or matching placebo for 24 months. The primary outcome was the change in AVC score. Selected secondary outcomes included change in aortic valve area and peak aortic jet velocity on echocardiography, heart valve surgery, change in aortic and coronary artery calcification, and change in dp-ucMGP (dephosphorylated-undercarboxylated matrix Gla-protein). Safety outcomes included all-cause death and cardiovascular events.

Results: From February 1, 2018, to March 21, 2019, 365 men were randomized. Mean age was 71.0 (±4.4) years. The mean (95% CI) increase in AVC score was 275 AU (95% CI, 225-326 AU) and 292 AU (95% CI, 246-338 AU) in the intervention and placebo groups, respectively. The mean difference on AVC progression was 17 AU (95% CI, -86 to 53 AU; P=0.64). The mean change in aortic valve area was 0.02 cm2 (95% CI, -0.09 to 0.12 cm2; P=0.78) and in peak aortic jet velocity was 0.04 m/s (95% CI, -0.11 to 0.02 m/s; P=0.21). The progression in aortic and coronary artery calcification score was not significantly different between patients treated with MK-7 plus vitamin D and patients receiving placebo. There was no difference in the rate of heart valve surgery (1 versus 2 patients; P=0.99), all-cause death (1 versus 4 patients; P=0.37), or cardiovascular events (10 versus 10 patients; P=0.99). Compared with patients in the placebo arm, a significant reduction in dp-ucMGP was observed with MK-7 plus vitamin D (-212 pmol/L versus 45 pmol/L; P<0.001).

Conclusions: In elderly men with an AVC score >300 AU, 2 years MK-7 plus vitamin D supplementation did not influence AVC progression.

Registration: URL: https://www.

Clinicaltrials: gov; Unique identifier: NCT03243890.

Keywords: aortic valve calcification; aortic valve stenosis; coronary artery calcification; coronary artery disease; matrix Gla protein; randomized controlled trial; vitamin K2.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Enrollment and randomization of patients. AVC indicates aortic valve calcification; and DANCAVAS, Danish Cardiovascular Screening.
Figure 2.
Figure 2.
Progression of aortic valve calcification. AVC progression according to treatment allocation for all patients (A), and stratified for baseline AVC score 300 to 599 (B) and ≥600 (C). Mean change from baseline with 95% CIs. AVC indicates aortic valve calcification; and MK-7, menaquinone-7.
Figure 3.
Figure 3.
Progression of aortic valve calcification. Aortic valve area (AVA; A) and peak aortic jet velocity (Vmax; B) changes according to treatment allocation. Mean change from baseline with 95% CIs. MK-7 indicates menaquinone-7.
Figure 4.
Figure 4.
Forest plot of stratified analyses of the primary outcome. dp-ucMGP indicates dephosphorylated-undercarboxylated matrix Gla-protein; and MK-7, menaquinone-7.
See this image and copyright information in PMC

Comment in

References

    1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–1011. doi: 10.1016/S0140-6736(06)69208-8 - PubMed
    1. Eveborn GW, Schirmer H, Heggelund G, Lunde P, Rasmussen K. The evolving epidemiology of valvular aortic stenosis. the Tromsø study. Heart. 2013;99:396–400. doi: 10.1136/heartjnl-2012-302265 - PubMed
    1. Pawade TA, Newby DE, Dweck MR. Calcification in aortic stenosis: the skeleton key. J Am Coll Cardiol. 2015;66:561–577. doi: 10.1016/j.jacc.2015.05.066 - PubMed
    1. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, et al. ; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356. doi: 10.1056/NEJMoa0804602 - PubMed
    1. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–2397. doi: 10.1056/NEJMoa043876 - PubMed

Publication types

Supplementary concepts

Associated data